Pharmacyte Biotech, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Pharmacyte Biotech, Inc. (PMCB) on November 18, 2022, reporting events that occurred on November 14, 2022. The company is incorporated in Nevada and its common stock trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing is a current report regarding corporate governance and personnel changes. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Corporate Actions
- Board Appointment: The Board increased its size to six members and appointed Robert Weinstein as a director effective immediately. Mr. Weinstein was also appointed Chair of the Audit Committee and a member of the Nominating Committee (contingent upon election at the annual meeting).
- Executive Appointment: Joshua Silverman was formally approved as Interim Chief Executive Officer and Interim President on a month-to-month basis.
- Compensation: Mr. Silverman's monthly salary was set at $31,250. Mr. Weinstein will receive standard cash compensation for non-employee directors.
- Bylaw Amendment: The Company amended its bylaws to remove the provision for cumulative voting in director elections, replacing it with a plurality voting standard.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of risks and contingencies. It strictly reports the immediate appointment of officers and directors and the amendment of corporate bylaws.
Key Facts for Investor Verification
- Verify the status of Robert Weinstein's election to the Board at the annual meeting scheduled for December 28, 2022.
- Confirm the duration of Joshua Silverman's interim role, as it is currently approved on a month-to-month basis.
- Review the full text of the Bylaw Amendment (Exhibit 3.1) to understand the specific implications of switching from cumulative to plurality voting.
- Check subsequent filings for the Company's financial position, as this 8-K does not disclose liquidity or debt levels.